Navigation Links
Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Date:6/8/2012

THE WOODLANDS, Texas, June 8, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012. 

Lexicon has completed dosing in a Phase 2b study of LX4211 in 299 patients with type 2 diabetes and expects to report top-line results at the end of June.

All posters will be available for download on Saturday morning from Lexicon's corporate website www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
2. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
3. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
4. Lexicon to Provide First Quarter 2012 Financial Results
5. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
6. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
7. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
8. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
9. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
10. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
11. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder ... Respiratory Inhalers - our new study reveals trends, R&D progress, and ... you are involved in this sector you must read this brand ... streams to 2027, assessing data, trends, opportunities and business prospects there. ... Discover how to ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor ... "The rubber bands used in conjunction with my braces always rubbed against the ... a way to prevent this problem." The O.B.S. was the result of his ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), will ... education conference for clinicians who manage some of the most difficult-to-treat forms of ... The program will be led by co- chairs Dr. John Marshall, chief of ...
Breaking Medicine News(10 mins):